40 kDa peginterferon alfa-2A (PEGASYS®): efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B: Graham E Cooksley, Royal Brisbane Hospital, Herston, Queensland Australia; Teerha Piratvisuth, Songklanakarin Hospital, Songkla Thailand; Yuan-Jen Wang, Teipei Veterans General Hospital, Taipei Taiwan; Varocha Mahachai, Chulalongkorn Hospital, Bangkok Thailand; You-Chen Chao, Tri Service General Hosptital, Taipei Taiwan; Tawesak Tanwandee, Siriraj Hospital, Bangkok Thailand; Anuchit Chutaputti, Pramongkutklao Hospital, Bangkok Thailand; Wen Yu Chang, Kaohsiung University Hospital, Kaohsiung Taiwan; Friederike E Zahm, Hoffmann-La Roche Basel Switzerland; Nigel Pluck, Roche Products Ltd, Welwyn Uk